Cancer

More than 2400 Canadians took to the streets of Toronto to raise an unprecedented $1.63 million for life-saving cancer research and clinical care at The Princess Margaret

Retrieved on: 
Sunday, June 16, 2024

This inclusive family and dog-friendly walk/run event has raised more than $16 million cumulatively in support of ground-breaking cancer research, treatment, and patient care at The Princess Margaret.

Key Points: 
  • This inclusive family and dog-friendly walk/run event has raised more than $16 million cumulatively in support of ground-breaking cancer research, treatment, and patient care at The Princess Margaret.
  • "I will continue to raise awareness and crucial funds to help the life-saving cancer research being done at the Princess Margaret Cancer Centre," says Brandon.
  • "I want to express my gratitude to the staff I encountered during my own cancer journey at Princess Margaret."
  • All routes passed by Princess Margaret Cancer Centre for celebratory photos, with pit stops and live entertainment along the way.

KPMG Launches "AI Impact Initiative" to Bring AI Technology to Non-Profits and Enable the AI Workforce of the Future

Retrieved on: 
Wednesday, June 12, 2024

Programs will responsibly enable non-profits to do more good with the latest AI technologies and help equip the future workforces with critical AI skills.

Key Points: 
  • New York, New York--(Newsfile Corp. - June 12, 2024) - KPMG LLP is proud to announce the launch of the " KPMG AI Impact Initiative ."
  • Equipping the workforce of the future with critical AI and generative AI (GenAI) skills and capabilities.
  • "We believe in the transformative power of AI and its potential to create positive change," said Anita Whitehead, Head of Impact and President of the KPMG US Foundation.
  • As KPMG embeds AI into every day at the firm, the AI Impact Initiative will bring that vision forward in how we give back to our communities.

Pacylex Publishes Phase 1 Safety and Efficacy of Zelenirstat in Cancer Patients in the Journal Investigational New Drugs

Retrieved on: 
Monday, June 10, 2024

Today Pacylex announced the publication of Phase 1 clinical trial results in the journal Investigational New Drugs.

Key Points: 
  • Today Pacylex announced the publication of Phase 1 clinical trial results in the journal Investigational New Drugs.
  • The report, titled: "A First-in-Human Phase I Trial of Daily Oral Zelenirstat, a N-myristoyltransferase Inhibitor, in Patients with Advanced Solid Tumors and Relapsed/Refractory B-cell Lymphomas," describes effects of zelenirstat at various doses on cancer patients who exhausted all other therapeutic options.
  • Zelenirstat was well tolerated, and adverse events were primarily gastrointestinal side effects, most of which resolved spontaneously without dose reduction.
  • Patients with heavily pre-treated colorectal, appendiceal, and ovarian cancers had 6 to 16 months of stable disease when treated with the recommended Phase 2 dose.

The Hunt for Virus Treatments Continues Post Covid-19

Retrieved on: 
Friday, June 7, 2024

Continued: "Scientists are on alert for changes in the virus that could signal that bird flu is adapting to spread more easily among humans.

Key Points: 
  • Continued: "Scientists are on alert for changes in the virus that could signal that bird flu is adapting to spread more easily among humans.
  • With global populations and economies still feeling the impact of Covid-19, any virus threat is going to make headlines.
  • "Additionally, in vitro, the Hemopurifier has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the reconstructed Spanish flu virus of 1918.
  • Both these workers experienced symptoms in the eye after coming into contact with dairy cows infected with the H5N1 virus."

Lifestyle Medicine by Dr. Ivan Rusilko Introduces New Methylene Blue Treatment

Retrieved on: 
Saturday, June 8, 2024

Los Angeles, California--(Newsfile Corp. - June 7, 2024) - Introducing methylene blue, a new treatment being offered at Lifestyle Medicine, under the leadership of the founder Dr. Ivan Rusilko.

Key Points: 
  • Los Angeles, California--(Newsfile Corp. - June 7, 2024) - Introducing methylene blue, a new treatment being offered at Lifestyle Medicine, under the leadership of the founder Dr. Ivan Rusilko.
  • Dr. Ivan Rusilko explains the potential cognitive enhancement and mood elevation capabilities of Lifestyle Medicine's new offering.
  • For Dr. Ivan's Lifestyle Medicine, Methylene Blue is anything but a new concept.
  • At Lifestyle Medicine, Rusilko offers Methylene Blue helping in reducing oxidative stress in patients.

EQS-News: QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments

Retrieved on: 
Monday, June 17, 2024

Vienna, Austria, 04 June 2024: QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim.

Key Points: 
  • Vienna, Austria, 04 June 2024: QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim.
  • Transcription factors are central regulators of gene expression that are commonly dysregulated in cancer and have remained largely unamenable to pharmacological intervention.
  • The joint R&D program, which was initiated in 2022, aims at changing the implied status quo via development of transformational, first-in-class cancer treatments.
  • The total potential transaction value may exceed EUR 500 million in form of R&D funding and success driven discovery, development, regulatory and commercial milestones.

EQS-News: Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs

Retrieved on: 
Monday, June 17, 2024

Tacalyx is a pioneer in the development of novel antibody-based therapeutics targeting TACAs, glycan structures that are often found on cancer cells but are absent from differentiated tissues under normal physiologic conditions.

Key Points: 
  • Tacalyx is a pioneer in the development of novel antibody-based therapeutics targeting TACAs, glycan structures that are often found on cancer cells but are absent from differentiated tissues under normal physiologic conditions.
  • With its unique expertise in glycan biology and manipulation, Tacalyx has established a pipeline of several first-in-class assets targeting different TACAs across multiple solid tumor indications.
  • To expand the development pipeline, Tacalyx has also established multiple academic collaborations to support the discovery of new TACAs.
  • With its platform, Tacalyx has developed a pipeline of seven projects targeting both known and novel TACAs with high relevance for human malignancies.

EQS-News: DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE

Retrieved on: 
Monday, June 17, 2024

Despite the impressive pro-killing abilities of the parent molecule, some cancer cell lines exhibited resistance.

Key Points: 
  • Despite the impressive pro-killing abilities of the parent molecule, some cancer cell lines exhibited resistance.
  • This prompted us to test additional Accum® variants, which led to the identification of the AccuTOX® molecule.
  • "This study presents insights of how the unconjugated AccuTOX® molecule works.
  • More specifically, we demonstrate that AccuTOX® displays improved killing efficiency, triggers immunogenic cell death and production of toxic byproducts while inducing endosomal breaks.

Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma

Retrieved on: 
Sunday, June 16, 2024

TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that 14-month median follow-up data from the pivotal Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) were shared during an oral presentation at the European Hematology Association (EHA) Congress 2024 and published in the Journal of Clinical Oncology. These longer-term results show a deepening of responses following the 11-month median follow-up data presented at the American Association for Cancer Research Annual Meeting in April. Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.

Key Points: 
  • These longer-term results show a deepening of responses following the 11-month median follow-up data presented at the American Association for Cancer Research Annual Meeting in April.
  • Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.
  • “Previous results from LINKER-MM1 have demonstrated that linvoseltamab has compelling efficacy characterized by deep and durable responses.
  • “Additionally, a study using US-based electronic health record data to indirectly compare linvoseltamab to real-world standard-of-care treatment also support the overall body of evidence for this investigational medicine in heavily pretreated multiple myeloma.

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

Retrieved on: 
Sunday, June 16, 2024

SAN FRANCISCO, June 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Bruton’s tyrosine kinase (BTK), being evaluated in an ongoing Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies, including CLL and non-Hodgkin lymphoma (NHL). Dr. Kim Linton, M.B.Ch.B, MRCP, Ph.D., FRCP, senior lecturer at the University of Manchester, a consultant at The Christie NHS Foundation Trust and an investigator on the clinical trial, presented the data in an oral session at the European Hematology Association Congress, which is being held from June 13–16, 2024, in Madrid, Spain.

Key Points: 
  • Patients were treated with NX-5948 at doses ranging from 50 mg to 600 mg once daily by oral administration.
  • NX-5948 was well tolerated across all doses evaluated with most common treatment emergent adverse events of purpura/contusion, thrombocytopenia and neutropenia.
  • Poor prognostic features were common including TP53 mutations (46.7%), and two patients (6.5%) had central nervous system (CNS) involvement.
  • A replay of the webcast and call will be archived on the Nurix website for approximately 30 days after the event.